These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Reversal of T cell anergy in leprosy patients: in vitro presentation with Mycobacterium leprae antigens using murabutide and Trat peptide in liposomal delivery. Sridevi K; Khanna N; Chattree V; Pal PC; Haq W; Rao DN Int Immunopharmacol; 2003 Nov; 3(12):1589-600. PubMed ID: 14555284 [TBL] [Abstract][Full Text] [Related]
3. Liposomes as carriers of antigens and adjuvants. Alving CR J Immunol Methods; 1991 Jun; 140(1):1-13. PubMed ID: 1712030 [TBL] [Abstract][Full Text] [Related]
4. Current status of immunological adjuvants. Warren HS; Vogel FR; Chedid LA Annu Rev Immunol; 1986; 4():369-88. PubMed ID: 2871847 [No Abstract] [Full Text] [Related]
5. Epitope specific immunity elicited by totally synthetic monovalent or polyvalent vaccines. Chedid L; Audibert F; Jolivet M; Carelli C; Uzan M; Gras-Masse H; Tarter A Ann Sclavo Collana Monogr; 1984; 1(2):77-85. PubMed ID: 6400358 [No Abstract] [Full Text] [Related]
6. Role of muramyl peptides for the enhancement of synthetic vaccines. Chedid L; Audibert F; Jolivet M Dev Biol Stand; 1986; 63():133-40. PubMed ID: 3527818 [TBL] [Abstract][Full Text] [Related]
7. Liposomes, muramyl dipeptide derivatives, and nontoxic lipid A derivatives as adjuvants for human malaria vaccines. Hui GS Am J Trop Med Hyg; 1994; 50(4 Suppl):41-51. PubMed ID: 8172331 [TBL] [Abstract][Full Text] [Related]
8. The immunopotentiating property of lipophilic muramyl dipeptide and its molecular state in liposomal membranes: plaque-forming cell responses and ESR studies. Manabe H; Utsumi H; Kusama T; Hamada A J Biochem; 1989 Jun; 105(6):861-3. PubMed ID: 2549019 [TBL] [Abstract][Full Text] [Related]
9. [Immunoadjuvant activities of bacterial cell wall components--with special reference to the effects of administration with various vehicles]. Kinoshita F Osaka Daigaku Shigaku Zasshi; 1978 Jun; 23(1):141-57. PubMed ID: 397324 [No Abstract] [Full Text] [Related]
10. Adjuvant formulations and their mode of action. Allison AC; Byars NE Semin Immunol; 1990 Sep; 2(5):369-74. PubMed ID: 1966859 [TBL] [Abstract][Full Text] [Related]
11. [New technology of vaccine production--international prospect of the development. Development of synthetic immunologic adjuvants and MDP-antigen binding vaccines]. Azuma I Nihon Rinsho; 1987 Oct; 45(10):2355-61. PubMed ID: 3448269 [No Abstract] [Full Text] [Related]
12. [Antitumor immunoadjuvants of microbial origin: the limitations in the immune system and microbial structure]. Cassone A Ann Ist Super Sanita; 1982; 18(3):497-500. PubMed ID: 6765082 [No Abstract] [Full Text] [Related]
13. [Stimulation of polymorphonuclear leukocytes by bacterial cell wall components and related synthetic compounds]. Ishihara Y J Osaka Univ Dent Sch; 1981 Jun; 26(1):105-20. PubMed ID: 6945420 [No Abstract] [Full Text] [Related]
14. Novel vaccination strategies for the control of mucosal infection. Husband AJ Vaccine; 1993; 11(2):107-12. PubMed ID: 8438609 [TBL] [Abstract][Full Text] [Related]
18. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles. Sabhnani L; Manocha M; Sridevi K; Shashikiran D; Rayanade R; Rao DN FEMS Immunol Med Microbiol; 2003 Oct; 38(3):215-29. PubMed ID: 14522457 [TBL] [Abstract][Full Text] [Related]
19. Developmental status of synthetic immunomodulators. Berendt MJ; Ives JL Year Immunol; 1985; ():193-201. PubMed ID: 2437723 [No Abstract] [Full Text] [Related]